Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
Medscape2h
Successful Pediatric Obesity Treatment Linked With Long-Term Health
The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...
4NVO : Decoding Novo Nordisk's Options Activity: What's...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Outsourcing-pharma19h
Novo Nordisk reports positive results for high-dose Wegovy formulation
Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...
Science Daily13h
Treatment for children with obesity has lasting effect
When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...
Is Novo Nordisk Stock a Buy?
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
FierceBiotech13d
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Novo Nordisk, other companies to meet Danish prime minister following Trump's Greenland threat
The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...
Finally An Attractive Entry Point Into Novo Nordisk
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...